TP53 and atypical teratoid rhabdoid tumor: demonstrated that gemcitabine enhances SIRT1 degradation in atypical teratoid rhabdoid tumors (ATRT), which in turn reactivates p53 and NF-κB signaling, promoting apoptosis, particularly in SHH-subtype tumors (215).